호르몬 대체요법(HRT) 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of hormone replacement therapy (HRT) Market

The global hormone replacement therapy (HRT) market is witnessing substantial growth, driven by the rising prevalence of menopausal disorders, growth hormone deficiencies, hypothyroidism, and male hypogonadism. According to Fortune Business Insights, the HRT market size was valued at USD 17.94 billion in 2025. The market is projected to grow to USD 19.04 billion in 2026 and further expand to USD 31.23 billion by 2034, reflecting a CAGR of 6.38% during the forecast period.

Market Dynamics

Hormone replacement therapies are critical for treating menopause-related symptoms in women, including hot flashes, sleep disorders, anxiety, and osteoporosis, as well as hormone-related deficiencies in men and children. For instance, growth hormone deficiency in adults and pediatric populations, hypothyroidism, and male hypogonadism are all driving the adoption of HRT globally. The growing awareness of modern therapies and increased acceptance of estrogen and combination therapy, as well as transdermal and oral formulations, are key factors supporting market expansion.

The market faced temporary setbacks during the COVID-19 pandemic, primarily due to shortages in supply and disruptions in healthcare facilities, which impacted diagnosis and treatment. However, resumption of healthcare services and continued demand for these therapies have restored growth to pre-pandemic levels.

Market Segmentation

By Therapy Type:

• Estrogen and Combination Therapy: Dominates the market with a projected 51.04% share globally in 2026, driven by awareness of menopausal symptoms and availability of multiple formulations such as gels, patches, and oral tablets. Notable product launches, including Bijuva/Bijuve by Theramex in Europe and the UK, are propelling growth.
• Growth Hormone Replacement Therapy (GHRT): Expected to witness strong CAGR due to rising prevalence of growth hormone deficiencies. Products like Norditropin (Novo Nordisk) and somatrogon (Pfizer/OPKO Health) are leading in revenue growth.
• Testosterone Therapy: Steady growth expected with approvals like Jatenzo (oral testosterone) and Tlando enhancing male hypogonadism treatment options.
• Thyroid Hormone Replacement Therapy: Growth is supported by increasing hypothyroidism prevalence and new product approvals, such as Thyquidity (VistaPharm, FDA-approved in 2020).

By Indication:

• Menopause: Largest segment with 56.8% market share in 2026, driven by the growing global population of menopausal women and increasing demand for estrogen-progesterone therapy.
• Hypothyroidism: Second-largest segment due to rising thyroid disorder prevalence.
• Growth Hormone Deficiency: A significant concern worldwide, with approximately 6,000 new adult cases annually in the U.S.
• Male Hypogonadism: Affecting 4-5 million men in the U.S., treatment adoption is increasing with new testosterone therapies.

By Route of Administration:

• Oral: Dominates globally due to widespread adoption and mass production.
• Transdermal: Growing significantly due to gel and patch formulations reducing risks associated with oral therapy.
• Parenteral: Expected to grow at the lowest rate.

By Distribution Channel:

• Hospital Pharmacies: Largest adoption due to the presence of pharmacies in multispecialty hospitals, ensuring therapy availability.
• Retail Pharmacies: Second-largest contributor, supported by over-the-counter HRT products.
• Online Pharmacies: Witnessing rapid growth, especially post-pandemic, driven by convenience and safety concerns.

Regional Insights

• North America: Dominates the market with 52.12% share in 2025, valued at USD 9.35 billion, projected to reach USD 9.9 billion in 2026. U.S. market expected to reach USD 8.45 billion in 2026. Growth driven by high prevalence of menopause, male hypogonadism, growth hormone deficiency, and high healthcare expenditure.
• Europe: Valued at USD 3.02 billion in 2025, projected to grow to USD 3.18 billion in 2026. The UK and Germany are key markets, with rising hormonal disorders in women and geriatric hypothyroidism driving demand.
• Asia Pacific: Market size of USD 3.03 billion in 2025, expected to reach USD 3.27 billion in 2026. Growth fueled by increased awareness of post-menopausal hazards, unmet medical needs, and novel therapy approvals in China and Japan.
• Latin America and Middle East & Africa: Smaller market share in 2025 (USD 1.14 billion and USD 1.4 billion, respectively), projected for moderate growth due to low awareness and unmet needs.

Market Trends and Growth Factors

• Launch of advanced drug delivery systems, such as transdermal patches, gels, and low-dose estrogen formulations, is driving market expansion.
• Increasing focus on personalized medicine and precision hormone therapy ensures tailored treatments considering genetics, lifestyle, and hormone levels.
• Rising prevalence of menopausal symptoms and growth hormone deficiency globally is encouraging new product development and R&D.
• Innovations like bioidentical hormone therapies and body-identical combination products, such as Bijuva/Bijuve, enhance safety and efficacy.

Restraining Factors

• Adverse effects, including blood clots, cholesterol changes, cardiovascular risks, and prostate issues, may limit adoption.
• High therapy costs, particularly for uninsured patients, pose a barrier.
• Regulatory challenges, delayed FDA approvals, and product recalls (e.g., Dr. Reddy's progesterone capsules, Perrigo Evamist spray) may impede growth.

Competitive Landscape

Key players in the global HRT market include:

• Novo Nordisk A/S (Denmark) - Leading with Norditropin and Sogroya for growth hormone deficiencies.
• Pfizer Inc. (U.S.) - Known for Genotropin and somatrogon development.
• AbbVie, Merck KGaA, Endo International, Allergan, Eli Lilly, Mithra Pharmaceuticals, Amgen - Active in product launches, approvals, and R&D.

Notable Developments:

• June 2023 - Pfizer reintroduced DUAVEE with enhanced packaging.
• June 2022 - Launch of Tlando (oral testosterone) in the U.S.
• May 2021 - Myovant Sciences received FDA approval for Myfembree.
• April 2021 - BIJUVE approved in U.K. and Belgium.
• October 2020 - Positive Phase 3 results for somatrogon in pediatric growth hormone deficiency.

Conclusion

The global hormone replacement therapy market is on a strong growth trajectory, expanding from USD 17.94 billion in 2025 to USD 31.23 billion by 2034, driven by increasing hormonal disorders, aging populations, and technological innovations in drug delivery. North America continues to lead the market, while Asia Pacific presents emerging opportunities. The combination of advanced therapies, personalized medicine, and strong R&D initiatives by key players like Novo Nordisk and Pfizer is expected to sustain long-term growth, despite challenges such as side effects, high costs, and regulatory hurdles.

Growth Rate CAGR of 6.38% from 2026-2034

By Therapy Type

• Estrogen and Combinations Replacement Therapy
• Thyroid Hormone Replacement Therapy
• Growth Hormone Replacement Therapy
• Testosterone Hormone Replacement Therapy

By Indication

• Menopause
• Hypothyroidism
• Male Hypogonadism
• Growth Hormone Deficiency

By Route of Administration

• Oral
• Transdermal
• Parenteral

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Geography

• North America (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country)
  • U.S.
  • Canada
• Europe (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country/Sub region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country/Sub region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country/Sub region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country/Sub region)
  • GCC
  • South Africa
  • Rest of the Middle East and Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Pipeline Analysis, By Key Players
• 4.2. Key Industry Developments - Mergers, Acquisitions, and Collaborations
• 4.3. New Product Launches, By Key Players
• 4.4. Impact of COVID-19 on the Global Hormone Replacement Therapy Market

5. Global Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Therapy Type
  • 5.1.1. Estrogen and Combinations Replacement Therapy
  • 5.1.2. Thyroid Hormone Replacement Therapy
  • 5.1.3. Growth Hormone Replacement Therapy
  • 5.1.4. Testosterone Hormone Replacement Therapy
• 5.2. Market Analysis, Insights and Forecast - By Indication
  • 5.2.1. Menopause
  • 5.2.2. Hypothyroidism
  • 5.2.3. Male hypogonadism
  • 5.2.4. Growth hormone deficiency
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Transdermal
  • 5.3.3. Parenteral
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospitals Pharmacies
  • 5.4.2. Retail Pharmacies & Drug Stores
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Therapy Type
  • 6.1.1. Estrogen and Combinations Replacement Therapy
  • 6.1.2. Thyroid Hormone Replacement Therapy
  • 6.1.3. Growth Hormone Replacement Therapy
  • 6.1.4. Testosterone Hormone Replacement Therapy
• 6.2. Market Analysis, Insights and Forecast - By Indication
  • 6.2.1. Menopause
  • 6.2.2. Hypothyroidism
  • 6.2.3. Male hypogonadism
  • 6.2.4. Growth hormone deficiency
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Transdermal
  • 6.3.3. Parenteral
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospitals Pharmacies
  • 6.4.2. Retail Pharmacies & Drug Stores
  • 6.4.3. Online Pharmacies
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Therapy Type
  • 7.1.1. Estrogen and Combinations Replacement Therapy
  • 7.1.2. Thyroid Hormone Replacement Therapy
  • 7.1.3. Growth Hormone Replacement Therapy
  • 7.1.4. Testosterone Hormone Replacement Therapy
• 7.2. Market Analysis, Insights and Forecast - By Indication
  • 7.2.1. Menopause
  • 7.2.2. Hypothyroidism
  • 7.2.3. Male hypogonadism
  • 7.2.4. Growth hormone deficiency
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Transdermal
  • 7.3.3. Parenteral
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospitals Pharmacies
  • 7.4.2. Retail Pharmacies & Drug Stores
  • 7.4.3. Online Pharmacies
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Therapy Type
  • 8.1.1. Estrogen and Combinations Replacement Therapy
  • 8.1.2. Thyroid Hormone Replacement Therapy
  • 8.1.3. Growth Hormone Replacement Therapy
  • 8.1.4. Testosterone Hormone Replacement Therapy
• 8.2. Market Analysis, Insights and Forecast - By Indication
  • 8.2.1. Menopause
  • 8.2.2. Hypothyroidism
  • 8.2.3. Male hypogonadism
  • 8.2.4. Growth hormone deficiency
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Transdermal
  • 8.3.3. Parenteral
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospitals Pharmacies
  • 8.4.2. Retail Pharmacies & Drug Stores
  • 8.4.3. Online Pharmacies
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Therapy Type
  • 9.1.1. Estrogen and Combinations Replacement Therapy
  • 9.1.2. Thyroid Hormone Replacement Therapy
  • 9.1.3. Growth Hormone Replacement Therapy
  • 9.1.4. Testosterone Hormone Replacement Therapy
• 9.2. Market Analysis, Insights and Forecast - By Indication
  • 9.2.1. Menopause
  • 9.2.2. Hypothyroidism
  • 9.2.3. Male hypogonadism
  • 9.2.4. Growth hormone deficiency
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Transdermal
  • 9.3.3. Parenteral
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospitals Pharmacies
  • 9.4.2. Retail Pharmacies & Drug Stores
  • 9.4.3. Online Pharmacies
• 9.5. Market Analysis, Insights and Forecast - By Country/ sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Therapy Type
  • 10.1.1. Estrogen and Combinations Replacement Therapy
  • 10.1.2. Thyroid Hormone Replacement Therapy
  • 10.1.3. Growth Hormone Replacement Therapy
  • 10.1.4. Testosterone Hormone Replacement Therapy
• 10.2. Market Analysis, Insights and Forecast - By Indication
  • 10.2.1. Menopause
  • 10.2.2. Hypothyroidism
  • 10.2.3. Male hypogonadism
  • 10.2.4. Growth hormone deficiency
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Transdermal
  • 10.3.3. Parenteral
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospitals Pharmacies
  • 10.4.2. Retail Pharmacies & Drug Stores
  • 10.4.3. Online Pharmacies
• 10.5. Market Analysis, Insights and Forecast - By Country/ sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2026)
• 11.2. Company Profiles
  • 11.2.1. Novo Nordisk A/S
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Pfizer Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. AbbVie Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Merck KGaA
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Endo Pharmaceuticals Solutions Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Allergan
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Eli Lilly and Company
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Mithra Pharmaceuticals
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Amgen
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)